Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma. Issue 5 (27th May 2022)

• Record Type: Journal Article
• Authors: Liu, Yin-Qiao; Chu, Ling-Yu; Yang, Tian; Zhang, Biao; Zheng, Zheng-Tan; Xie, Jian-Jun; Xu, Yi-Wei; Fang, Wang-Kai
• Is Part Of: Bioscience reports. Volume 42:Issue 5(2022)
• Publication Date: 2022-05-27
• Subjects: diagnosis -- DSG2 -- esophageal squamous cell carcinoma -- esophagogastric junction adenocarcinoma -- serum biomarker; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20212612
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Background : Exploration of serum biomarkers for early detection of upper gastrointestinal cancer is required. Here, we aimed to evaluate the diagnostic potential of serum desmoglein-2 (DSG2) in patients with esophageal squamous cell carcinoma (ESCC) and esophagogastric junction adenocarcinoma (EJA). Methods : Serum DSG2 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 459 participants including 151 patients with ESCC, 96 with EJA, and 212 healthy controls. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic accuracy. Results : Levels of serum DSG2 were significantly higher in patients with ESCC and EJA than those in healthy controls ( P <0.001). Detection of serum DSG2 demonstrated an area under the ROC curve (AUC) value of 0.724, sensitivity of 38.1%, and specificity of 84.8% for the diagnosis of ESCC in the training cohort, and AUC 0.736, sensitivity 58.2%, and specificity 84.7% in the validation cohort. For diagnosis of EJA, measurement of DSG2 provided a sensitivity of 29.2%, a specificity of 90.2%, and AUC of 0.698. Similar results were observed for the diagnosis of early-stage ESCC (AUC 0.715 and 0.722, sensitivity 36.3 and 50%, and specificity 84.8 and 84.7%, for training and validation cohorts, respectively) and early-stage EJA (AUC 0.704, sensitivity 44.4%, and specificity 86.9%). Analysis of clinical data indicated that DSG2 levels were significantly associated with patient age and histological grade in ESCC ( P <0.05). Conclusion : Serum DSG2 may be a diagnostic biomarker for ESCC and EJA.